665 related articles for article (PubMed ID: 26660519)
41. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
42. The use of ibrutinib in chronic lymphocytic leukemia.
Damon LE
Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
[No Abstract] [Full Text] [Related]
43. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R
Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755
[TBL] [Abstract][Full Text] [Related]
44. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
45. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Manukyan G; Turcsanyi P; Mikulkova Z; Gabcova G; Urbanova R; Gajdos P; Smotkova Kraiczova V; Zehnalova S; Papajik T; Kriegova E
Leuk Res; 2018 Sep; 72():113-119. PubMed ID: 30149317
[TBL] [Abstract][Full Text] [Related]
46. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
47. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
Shen Y; Best OG; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2018 Aug; 59(8):1927-1937. PubMed ID: 29164976
[TBL] [Abstract][Full Text] [Related]
48. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065
[TBL] [Abstract][Full Text] [Related]
49. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
[TBL] [Abstract][Full Text] [Related]
50. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
[TBL] [Abstract][Full Text] [Related]
51. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner A
Blood; 2012 Dec; 120(24):4684-91. PubMed ID: 22875912
[TBL] [Abstract][Full Text] [Related]
52. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA
J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319
[TBL] [Abstract][Full Text] [Related]
53. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Chang BY; Francesco M; De Rooij MF; Magadala P; Steggerda SM; Huang MM; Kuil A; Herman SE; Chang S; Pals ST; Wilson W; Wiestner A; Spaargaren M; Buggy JJ; Elias L
Blood; 2013 Oct; 122(14):2412-24. PubMed ID: 23940282
[TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
55. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Leuk Lymphoma; 2018 Nov; 59(11):2686-2691. PubMed ID: 29465264
[TBL] [Abstract][Full Text] [Related]
56. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Pavlasova G; Borsky M; Seda V; Cerna K; Osickova J; Doubek M; Mayer J; Calogero R; Trbusek M; Pospisilova S; Davids MS; Kipps TJ; Brown JR; Mraz M
Blood; 2016 Sep; 128(12):1609-13. PubMed ID: 27480113
[TBL] [Abstract][Full Text] [Related]
57. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
[TBL] [Abstract][Full Text] [Related]
58. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Trimarco V; Ave E; Facco M; Chiodin G; Frezzato F; Martini V; Gattazzo C; Lessi F; Giorgi CA; Visentin A; Castelli M; Severin F; Zambello R; Piazza F; Semenzato G; Trentin L
Oncotarget; 2015 Dec; 6(39):42130-49. PubMed ID: 26517523
[TBL] [Abstract][Full Text] [Related]
59. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
[TBL] [Abstract][Full Text] [Related]
60. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
de Weerdt I; Hofland T; Lameris R; Endstra S; Jongejan A; Moerland PD; de Bruin RCG; Remmerswaal EBM; Ten Berge IJM; Liu N; van der Stelt M; Faber LM; Levin MD; Eldering E; Tonino SH; de Gruijl TD; van der Vliet HJ; Kater AP
Blood; 2018 Nov; 132(21):2260-2272. PubMed ID: 30213872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
